Posted by Michael Wonder on 18 Sep 2018
FDA grants Lin BioScience rare paediatric disease status for LBS-008 to treat Stargardt disease
17 September 2018 - Designation enhances FDA orphan drug designation for Phase I candidate targeting incurable blindness in children.
Lin BioScience announced today that the US FDA has granted rare paediatric disease designation to LBS-008, a first-in-class oral therapy for the treatment of Stargardt disease.
LBS-008 is a first-in-class oral therapy that prevents the buildup of toxins in the eye that cause Stargardt disease and atrophic age-related macular degeneration.
Read Lin BioScience press release
